Locoregional treatment of brain tumours

Glioblastoma multiforme (GBM), primary brain tumor is the most common and most malignant of the glia tumors. It is characterized by the worst prognosis with a median overall survival time of only 9-15 months. The infiltrating character of the tumor, its molecular heterogeneity, as well as the protective effects of the blood-brain barrier are the main causes for the insufficiency of established front line treatments (surgery, radio- and chemotherapy). The best treatment strategy for patients with recurrent GBM is unclear and controversial. Even with established state of the art treatment in almost 90% of patients the recurrence of disease is observed and median survival after recurrence is less than 6 months. An alternative method of treatment is to apply the drug locally. It has been shown that GBM overexpresses the of NK-1 receptor and substance P (SP) can be used as a ligand. Alpha emitters, with shorter range and higher energy than beta emitters, offer the new potential for selective irradiation of tumors, with minimizing damage to adjacent tissue. This chapter describes the use of radiolabeled SP for intratumoral treatment of the glia tumors.

KUNIKOWSKA Jolanta;  MORGENSTERN Alfred;  BRUCHERTSEIFER Frank;  KROLICKI Leszek; 

2018-05-03

Springer

JRC106456

978-3-319-63066-3,    978-3-319-63067-0,   

https://publications.jrc.ec.europa.eu/repository/handle/JRC106456,   

10.1007/978-3-319-63067-0_35,